Holen Sie sich die Stockscreener-App
155.00
1.47%
2.25
Handel nachbörslich:
155.00
Schlusskurs vom Vortag:
$152.75
Offen:
$153.34
24-Stunden-Volumen:
2.21M
Relative Volume:
2.37
Marktkapitalisierung:
$7.63B
Einnahmen:
$4.06B
Nettoeinkommen (Verlust:
$413.08M
KGV:
19.35
EPS:
8.01
Netto-Cashflow:
$560.48M
1W Leistung:
+3.11%
1M Leistung:
-2.76%
6M Leistung:
+1.19%
1J Leistung:
-23.83%
1-Tages-Spanne:
$151.56
$155.43
1-Wochen-Bereich:
$145.99
$155.43
52-Wochen-Spanne:
$91.86
$230.02
Charles River Laboratories International Inc Stock (CRL) Company Profile
Firmenname
Charles River Laboratories International Inc
Sektor
Branche
Telefon
781-222-6000
Adresse
251 BALLARDVALE ST, WILMINGTON, MA
Vergleichen Sie CRL mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
CRL
Charles River Laboratories International Inc
|
155.00 | 7.52B | 4.06B | 413.08M | 560.48M | 8.01 |
|
TMO
Thermo Fisher Scientific Inc
|
484.79 | 180.28B | 43.21B | 6.58B | 6.17B | 17.29 |
|
DHR
Danaher Corp
|
209.14 | 147.31B | 24.01B | 3.41B | 4.86B | 4.70 |
|
IDXX
Idexx Laboratories Inc
|
663.92 | 52.18B | 4.04B | 985.66M | 774.34M | 12.01 |
|
A
Agilent Technologies Inc
|
120.29 | 33.33B | 6.63B | 1.17B | 1.19B | 4.05 |
|
IQV
Iqvia Holdings Inc
|
190.23 | 31.60B | 15.50B | 1.33B | 2.16B | 7.34 |
Charles River Laboratories International Inc Stock (CRL) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-07-09 | Hochstufung | Citigroup | Neutral → Buy |
| 2025-05-23 | Hochstufung | Redburn Atlantic | Neutral → Buy |
| 2025-05-14 | Hochstufung | TD Cowen | Hold → Buy |
| 2025-05-08 | Hochstufung | Evercore ISI | In-line → Outperform |
| 2025-03-21 | Herabstufung | Goldman | Buy → Neutral |
| 2025-03-04 | Hochstufung | Citigroup | Sell → Neutral |
| 2025-03-03 | Hochstufung | Redburn Atlantic | Sell → Neutral |
| 2025-01-22 | Herabstufung | William Blair | Outperform → Mkt Perform |
| 2025-01-17 | Herabstufung | UBS | Buy → Neutral |
| 2024-11-18 | Herabstufung | CLSA | Hold → Underperform |
| 2024-11-07 | Hochstufung | CLSA | Underperform → Hold |
| 2024-10-23 | Eingeleitet | CLSA | Underperform |
| 2024-10-14 | Eingeleitet | Redburn Atlantic | Sell |
| 2024-10-07 | Herabstufung | Evercore ISI | Outperform → In-line |
| 2024-10-02 | Herabstufung | BofA Securities | Buy → Neutral |
| 2024-10-01 | Herabstufung | Citigroup | Neutral → Sell |
| 2024-08-08 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2024-08-08 | Herabstufung | Robert W. Baird | Outperform → Neutral |
| 2024-06-28 | Herabstufung | Argus | Buy → Hold |
| 2024-06-07 | Eingeleitet | Mizuho | Neutral |
| 2024-06-06 | Eingeleitet | Goldman | Buy |
| 2024-02-15 | Herabstufung | Guggenheim | Buy → Neutral |
| 2023-09-13 | Eingeleitet | TD Cowen | Market Perform |
| 2023-07-10 | Herabstufung | Citigroup | Buy → Neutral |
| 2023-02-23 | Hochstufung | Guggenheim | Neutral → Buy |
| 2023-01-12 | Herabstufung | Jefferies | Buy → Hold |
| 2022-09-30 | Hochstufung | Jefferies | Hold → Buy |
| 2022-08-25 | Eingeleitet | Credit Suisse | Outperform |
| 2022-08-04 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2022-05-24 | Eingeleitet | Guggenheim | Neutral |
| 2022-04-25 | Herabstufung | Jefferies | Buy → Hold |
| 2022-04-07 | Eingeleitet | Stephens | Overweight |
| 2022-02-17 | Bestätigt | BofA Securities | Buy |
| 2022-02-17 | Hochstufung | Citigroup | Neutral → Buy |
| 2022-02-17 | Bestätigt | Deutsche Bank | Buy |
| 2022-02-17 | Bestätigt | Morgan Stanley | Overweight |
| 2022-02-17 | Bestätigt | UBS | Buy |
| 2021-08-05 | Fortgesetzt | Credit Suisse | Neutral |
| 2020-12-16 | Herabstufung | Citigroup | Buy → Neutral |
| 2020-09-10 | Hochstufung | Jefferies | Hold → Buy |
| 2020-07-01 | Hochstufung | BofA Securities | Neutral → Buy |
| 2020-05-13 | Hochstufung | UBS | Neutral → Buy |
| 2020-04-21 | Herabstufung | Jefferies | Buy → Hold |
| 2020-03-27 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2020-03-02 | Eingeleitet | Deutsche Bank | Buy |
| 2020-02-18 | Hochstufung | Wolfe Research | Peer Perform → Outperform |
| 2020-01-10 | Hochstufung | Goldman | Neutral → Buy |
| 2020-01-08 | Eingeleitet | Wells Fargo | Overweight |
| 2020-01-07 | Eingeleitet | Citigroup | Buy |
| 2019-10-18 | Herabstufung | BofA/Merrill | Buy → Neutral |
| 2019-06-10 | Eingeleitet | SVB Leerink | Outperform |
| 2019-04-30 | Fortgesetzt | Evercore ISI | Outperform |
| 2018-12-14 | Eingeleitet | Deutsche Bank | Buy |
| 2018-10-09 | Eingeleitet | UBS | Neutral |
| 2018-08-23 | Hochstufung | Raymond James | Mkt Perform → Outperform |
| 2018-07-17 | Hochstufung | RBC Capital Mkts | Sector Perform → Outperform |
| 2018-06-15 | Hochstufung | KeyBanc Capital Mkts | Sector Weight → Overweight |
| 2018-02-14 | Hochstufung | SunTrust | Hold → Buy |
Alle ansehen
Charles River Laboratories International Inc Aktie (CRL) Neueste Nachrichten
Do Charles River (CRL) Earnings Trends Reveal Shifting Priorities in Its Advanced Therapeutics Ambitions? - simplywall.st
5 Revealing Analyst Questions From Charles River Laboratories’s Q2 Earnings Call - Yahoo Finance
Stock Analysis | Charles River Laboratories International OutlookMixed Technical Signals and Strong Fundamentals - AInvest
Centene, RadNet, Evolent Health, Illumina, and Charles River Laboratories Shares Are Soaring, What You Need To Know - Yahoo Finance
CRL Stock Gains on Q2 Earnings and Revenue Beat, Raises '25 View - MSN
Interpreting Charles River (CRL) International Revenue Trends - Yahoo Finance
Charles River Laboratories International Inc. Recovery Linked to Earnings SurprisePattern Alert With ROI Driven Strategy Shared - metal.it
Charles River Laboratories Q2 2025 Earnings Call Transcript Summary - AInvest
Charles River Laboratories International Inc's Q2 2025 Financials and Strategic Direction: A SWOT Analysis - AInvest
Charles River Laboratories Reports Q2 2025 Earnings - The Globe and Mail
Charles River Laboratories International Inc. stock underperforms Wednesday when compared to competitors - MSN
Charles River Laboratories International 2025 Q2 Earnings Misses Targets as Net Income Drops 44% - AInvest
Charles River Laboratories International, Inc. (NYSE:CRL) Q2 2025 Earnings Call Transcript - Insider Monkey
Charles River Laboratories International Second Quarter 2025 Earnings: Revenues Beat Expectations, EPS Lags - Yahoo Finance
Charles River Laboratories Q2 2025 Earnings Preview - MSN
Why Charles River Laboratories International Inc. stock attracts strong analyst attentionWeekly Hot Picks With Buy Confidence Released - beatles.ru
Charles River Laboratories International Q2 2025 Earnings Call Transcript - MarketBeat
Charles River Laboratories International 2025 Q2 Earnings Beats Expectations as Net Income Drops 44.1% - AInvest
Charles River: Q2 Earnings Snapshot - Milford Mirror
Charles River Labs Reports Mixed Q2 Earnings Call - TipRanks
Charles River Laboratories Shares Drop 10.25% Despite 49.73% Volume Surge Ranking 339th in Market Activity as Order Cancellations Weigh on Investor Sentiment - AInvest
Charles River (CRL) Q2 EPS Jumps 11% - The Globe and Mail
Charles River (CRL) Q2 EPS Jumps 11% - The Motley Fool
Charles River Labs stock price target raised to $175 by BofA Securities - Investing.com India
Charles River Laboratories Q2 2025 Earnings Call Transcript Review - AInvest
Charles River Sees Limited Impact From NIH Cuts, Tariffs, Drug Pricing - Benzinga
Charles River: Margin Fears Outweigh Solid Q2 (NYSE:CRL) - Seeking Alpha
Charles River Labs cleared in DOJ monkey investigation, provides strategic review update - The Business Journals
Deutsche Bank Adjusts Price Target on Charles River Laboratories International to $185 From $180 - MarketScreener
Charles River Laboratories (CRL) Q2 Earnings and Revenues Surpass Estimates - sharewise.com
Charles River (CRL) Q2 Earnings: Taking a Look at Key Metrics Versus Estimates - Yahoo Finance
Charles River Laboratories (NYSE:CRL) Delivers Impressive Q2 - Yahoo Finance
Charles River Labs Q2 2025 slides: Beats expectations, raises guidance amid stabilizing demand - Investing.com Canada
Charles River Laboratories Announces Second-Quarter 2025 Results - BioSpace
Charles River Laboratories Fiscal Q2 Non-GAAP Earnings, Revenue Rise; 2025 Outlook Updated - MarketScreener
Charles River Laboratories Reports Q2 2025 Revenue of $1.03 Bill - GuruFocus
Charles River Labs soars 6.9% after crushing Q2 earnings expectations By Investing.com - Investing.com South Africa
Charles River Labs soars 6.9% after crushing Q2 earnings expectations - Investing.com
Charles River Laboratories earnings beat by $0.62, revenue topped estimates - Investing.com Canada
Charles River Laboratories (CRL) Reports Earnings Tomorrow: What To Expect - Yahoo Finance
How volatile is Charles River Laboratories International Inc. stock compared to the marketBuild wealth steadily with proven strategies - Jammu Links News
Charles River Laboratories International Inc. Stock Analysis and ForecastFree Stock Market Knowledge Sharing - Jammu Links News
What is Charles River Laboratories International Inc. company’s growth strategyBuild a winning investment portfolio - Jammu Links News
Is it the right time to buy Charles River Laboratories International Inc. stockIdentify winners with top-tier analysis - Jammu Links News
What is the dividend policy of Charles River Laboratories International Inc. stockRobust investment performance - Jammu Links News
How strong is Charles River Laboratories International Inc. company’s balance sheetMarket-leading profit generation - Jammu Links News
What are Charles River Laboratories International Inc. company’s key revenue driversAchieve breakthrough gains with expert advice - Jammu Links News
Finanzdaten der Charles River Laboratories International Inc-Aktie (CRL)
Umsatz
Nettogewinn
Free Cashflow
ENV
3.96%
1.32%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):